A citation-based method for searching scientific literature

Ryo Suzuki, Jun-Ichi Eiki, Takashi Moritoyo, Kenichi Furihata, Akira Wakana, Yukari Ohta, Shigeru Tokita, Takashi Kadowaki. Diabetes Obes Metab 2018
Times Cited: 4







List of co-cited articles
15 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


The efficacy and safety of adding either vildagliptin or glimepiride to ongoing metformin therapy in patients with type 2 diabetes mellitus.
Gyuri Kim, Sewon Oh, Sang-Man Jin, Kyu Yeon Hur, Jae Hyeon Kim, Moon-Kyu Lee. Expert Opin Pharmacother 2017
15
75

Mean amplitude of glycemic excursions, a measure of diabetic instability.
F J Service, G D Molnar, J W Rosevear, E Ackerman, L C Gatewood, W F Taylor. Diabetes 1970
823
75

Glycemic variability correlates strongly with postprandial beta-cell dysfunction in a segment of type 2 diabetic patients using oral hypoglycemic agents.
Klaus-Dieter Kohnert, Petra Augstein, Eckhard Zander, Peter Heinke, Karolina Peterson, Ernst-Joachim Freyse, Roman Hovorka, Eckhard Salzsieder. Diabetes Care 2009
72
50


Comparison of the effects of gemigliptin and dapagliflozin on glycaemic variability in type 2 diabetes: A randomized, open-label, active-controlled, 12-week study (STABLE II study).
Soo Heon Kwak, You-Cheol Hwang, Jong Chul Won, Ji Cheol Bae, Hyun Jin Kim, Sunghwan Suh, Eun Young Lee, Subin Lee, Sang-Yong Kim, Jae Hyeon Kim. Diabetes Obes Metab 2020
6
50

Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes.
Bo Ahrén, Anja Schweizer, Sylvie Dejager, Beth E Dunning, Peter M Nilsson, Margaretha Persson, James E Foley. J Clin Endocrinol Metab 2009
136
50


Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR).
Ayako Fuchigami, Fumika Shigiyama, Toru Kitazawa, Yosuke Okada, Takamasa Ichijo, Mariko Higa, Toru Hiyoshi, Ikuo Inoue, Kaoru Iso, Hidenori Yoshii,[...]. Cardiovasc Diabetol 2020
21
50

Favourable effect of the sodium-glucose co-transporter-2 inhibitor canagliflozin plus the dipeptidyl peptidase-4 inhibitor teneligliptin in combination on glycaemic fluctuation: An open-label, prospective, randomized, parallel-group comparison trial (the CALMER study).
Kyu Yong Cho, Hiroshi Nomoto, Akinobu Nakamura, Shinichiro Kawata, Hajime Sugawara, Jun Takeuchi, So Nagai, Kazuhisa Tsuchida, Kazuno Omori, Hiroki Yokoyama,[...]. Diabetes Obes Metab 2020
6
50

Add-on treatment with teneligliptin ameliorates glucose fluctuations and improves glycemic control index in Japanese patients with type 2 diabetes on insulin therapy.
Seiichi Tanaka, Kunihiro Suzuki, Chie Aoki, Mai Niitani, Kanako Kato, Takanori Tomotsune, Yoshimasa Aso. Diabetes Technol Ther 2014
17
50

Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy.
Bo Ahrén, James E Foley, Ele Ferrannini, David R Matthews, Bernard Zinman, Sylvie Dejager, Vivian A Fonseca. Diabetes Care 2010
66
50

Effects of add-on treatment with sitagliptin on narrowing the range of glucose fluctuations in Japanese type 2 diabetes patients receiving insulin therapy.
Yutaka Mori, Yukiko Taniguchi, Shigeru Miyazaki, Junichi Yokoyama, Kazunori Utsunomiya. Diabetes Technol Ther 2013
19
50

Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes.
V Fonseca, A Schweizer, D Albrecht, M A Baron, I Chang, S Dejager. Diabetologia 2007
289
50

Effects of Vildagliptin Add-on Insulin Therapy on Nocturnal Glycemic Variations in Uncontrolled Type 2 Diabetes.
Feng-Fei Li, Yun Shen, Rui Sun, Dan-Feng Zhang, Xing Jin, Xiao-Fang Zhai, Mao-Yuan Chen, Xiao-Fei Su, Jin-Dan Wu, Lei Ye,[...]. Diabetes Ther 2017
7
50

Efficacy of Vildagliptin Added to Continuous Subcutaneous Insulin Infusion (CSII) in Hospitalized Patients with Type 2 Diabetes.
Fu-Ping Lyu, Bing-Kun Huang, Wei-Juan Su, Fang-Fang Yan, Jin-Yang Zeng, Zheng Chen, Yu-Xian Zhang, Shun-Hua Wang, Yin-Xiang Huang, Mu-Lin Zhang,[...]. Diabetes Ther 2020
2
100

The Diabetic Foot as a Proxy for Cardiovascular Events and Mortality Review.
Isa Dietrich, Gustavo Arruda Braga, Fernanda Gomes de Melo, Ana Carolina Calmon da Costa Silva Silva. Curr Atheroscler Rep 2017
34
25

Vildagliptin reduces plasma stromal cell-derived factor-1α in patients with type 2 diabetes compared with glimepiride.
Kyeong Seon Park, SooHeon Kwak, Young Min Cho, Kyong Soo Park, Hak C Jang, Seong Yeon Kim, Hye Seung Jung. J Diabetes Investig 2017
11
25

Meta-regression detected associations between heterogeneous treatment effects and study-level, but not patient-level, factors.
Christopher H Schmid, Paul C Stark, Jesse A Berlin, Paul Landais, Joseph Lau. J Clin Epidemiol 2004
167
25

The relative importance of vascular structure and function in predicting cardiovascular events.
Robert Fathi, Brian Haluska, Nicole Isbel, Leanne Short, Thomas H Marwick. J Am Coll Cardiol 2004
157
25

The synergistic effects of saxagliptin and metformin on CD34+ endothelial progenitor cells in early type 2 diabetes patients: a randomized clinical trial.
Fiona J Dore, Cleyton C Domingues, Neeki Ahmadi, Nabanita Kundu, Yana Kropotova, Sara Houston, Carol Rouphael, Aytan Mammadova, Linda Witkin, Anamil Khiyami,[...]. Cardiovasc Diabetol 2018
17
25

A randomized controlled trial comparing the effects of dapagliflozin and DPP-4 inhibitors on glucose variability and metabolic parameters in patients with type 2 diabetes mellitus on insulin.
Hiroshi Nomoto, Hideaki Miyoshi, Hajime Sugawara, Kota Ono, Shingo Yanagiya, Mayuko Oita, Akinobu Nakamura, Tatsuya Atsumi. Diabetol Metab Syndr 2017
17
25

Treatment intensification in patients with type 2 diabetes who failed metformin monotherapy.
A Z Fu, Y Qiu, M J Davies, L Radican, S S Engel. Diabetes Obes Metab 2011
58
25

Evaluation of 1,5-anhydroglucitol as a marker for glycemic variability in patients with type 2 diabetes mellitus.
Min Joo Kim, Hye Seung Jung, Yul Hwang-Bo, Sun Wook Cho, Hak Chul Jang, Seong Yeon Kim, Kyong Soo Park. Acta Diabetol 2013
25
25

Effect of gemigliptin on glycaemic variability in patients with type 2 diabetes (STABLE study).
Se E Park, Byung W Lee, Jae H Kim, Woo J Lee, Jae H Cho, Chang H Jung, Seung H Lee, Sunghwan Suh, Gwong C Hur, Sung H Kim,[...]. Diabetes Obes Metab 2017
17
25

Incretin-based drugs for type 2 diabetes: Focus on East Asian perspectives.
Yutaka Seino, Hitoshi Kuwata, Daisuke Yabe. J Diabetes Investig 2016
104
25

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
David Moher, Alessandro Liberati, Jennifer Tetzlaff, Douglas G Altman. PLoS Med 2009
25

1,5-anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes.
Kathleen M Dungan, John B Buse, Joseph Largay, Mary M Kelly, Eric A Button, Shuhei Kato, Steven Wittlin. Diabetes Care 2006
170
25


Measuring inconsistency in meta-analyses.
Julian P T Higgins, Simon G Thompson, Jonathan J Deeks, Douglas G Altman. BMJ 2003
25


The biology of incretin hormones.
Daniel J Drucker. Cell Metab 2006
25

GRADE guidelines: 3. Rating the quality of evidence.
Howard Balshem, Mark Helfand, Holger J Schünemann, Andrew D Oxman, Regina Kunz, Jan Brozek, Gunn E Vist, Yngve Falck-Ytter, Joerg Meerpohl, Susan Norris,[...]. J Clin Epidemiol 2011
25


Is HbA(1c) affected by glycemic instability?
Rachel Derr, Elizabeth Garrett, Gerald A Stacy, Christopher D Saudek. Diabetes Care 2003
98
25

Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis.
J A Hirst, A J Farmer, A Dyar, T W C Lung, R J Stevens. Diabetologia 2013
72
25

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Anushka Patel, Stephen MacMahon, John Chalmers, Bruce Neal, Laurent Billot, Mark Woodward, Michel Marre, Mark Cooper, Paul Glasziou, Diederick Grobbee,[...]. N Engl J Med 2008
25

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.
I M Stratton, A I Adler, H A Neil, D R Matthews, S E Manley, C A Cull, D Hadden, R C Turner, R R Holman. BMJ 2000
25

Bias in meta-analysis detected by a simple, graphical test.
M Egger, G Davey Smith, M Schneider, C Minder. BMJ 1997
25



Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Melanie J Davies, David A D'Alessio, Judith Fradkin, Walter N Kernan, Chantal Mathieu, Geltrude Mingrone, Peter Rossing, Apostolos Tsapas, Deborah J Wexler, John B Buse. Diabetes Care 2018
991
25

Effects of sitagliptin as initial therapy in newly diagnosed elderly type 2 diabetics: A randomized controlled study.
Xiaoyan Xiao, Xiaopei Cui, Jianbo Zhang, Zhenxia Han, Yu Xiao, Nan Chen, Baoying Li, Mei Cheng, Haiqing Gao, Kuanxiao Tang. Exp Ther Med 2016
1
100

Intermittent high glucose enhances apoptosis in human umbilical vein endothelial cells in culture.
A Risso, F Mercuri, L Quagliaro, G Damante, A Ceriello. Am J Physiol Endocrinol Metab 2001
276
25

Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006.
Bernard M Y Cheung, Kwok Leung Ong, Stacey S Cherny, Pak-Chung Sham, Annette W K Tso, Karen S L Lam. Am J Med 2009
283
25

Slow response to loss of glycemic control in type 2 diabetes mellitus.
Jonathan B Brown, Gregory A Nichols. Am J Manag Care 2003
77
25



Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus.
B Richter, E Bandeira-Echtler, K Bergerhoff, C L Lerch. Cochrane Database Syst Rev 2008
209
25


The Cochrane Collaboration's tool for assessing risk of bias in randomised trials.
Julian P T Higgins, Douglas G Altman, Peter C Gøtzsche, Peter Jüni, David Moher, Andrew D Oxman, Jelena Savovic, Kenneth F Schulz, Laura Weeks, Jonathan A C Sterne. BMJ 2011
25


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.